Figure 4. Therapeutic effects of intratumoral injection of CAR-expressing NK-92 cells against subcutaneous Daudi lymphomas. NOD/SCID mice (n = 5) were injected subcutaneously with 2.5 × 105 natural killer (NK) cell-resistant luciferase (Luc)-expressing DaudiNKR cells in PBS. When the tumor had grown to about 0.5 cm3, mice were treated with intratumoral injections of 5 × 106 parental NK-92 cells (w.t.), 5 × 106 NK-92 cells expressing CD19-targeting chimeric antigen receptors (αCD19-CAR), or 5 × 106 NK-92 cells expressing CD20-targeting CAR (αCD20-CAR), on days 4, 5, 6. Results are expressed as fold change in bioluminescence before and after the injection of NK-92 cells. Data relative to each mouse are shown for cohorts of animals treated with NK-92 cells expressing CD19- (black diamonds) or CD20-targeting (black triangles) CARs, treated with parental NK-92 cells (white squares), or treated with PBS (x marks). Mean values (black lines) are also shown for each cohort.